Olodaterol
As of the edition of 20 October 2026, Olodaterol is a small molecule: marketed, first approved in 2013 (ES); acts on ADRB2; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Striverdi Respimat
- First approved
- 3 December 2013 (ES)
- Approvals on record
- 8 in 6 regions
- Holder of the most recent approval
- Boehringer Ingelheim; 2 holders in all
- Registered trials
- 75, 3 stopped early
- Disease areas
- Lungs and airways; Immune system; Digestive system
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Boehringer Ingelheim.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 14 | 0 | 0 |
| Phase 1 | 14 | 13 | 0 | 1 |
| Phase 2 | 10 | 9 | 0 | 1 |
| Phase 3 | 26 | 26 | 0 | 0 |
| Phase 4 | 10 | 9 | 0 | 1 |
| All trials | 75 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Originator and Lead sponsor of trials | 2005 to now |